Screening of Kabasura Kudineer Chooranam against COVID-19 through Targeting of Main Protease and RNA-Dependent RNA Polymerase of SARS-CoV-2 by Molecular Docking Studies
GOPALASATHEESKUMAR K, Karthikeyen Lakshmanan, Anguraj Moulishankar, J. Suresh, D. K. Babu, V. Kalaichelvan
{"title":"Screening of Kabasura Kudineer Chooranam against COVID-19 through Targeting of Main Protease and RNA-Dependent RNA Polymerase of SARS-CoV-2 by Molecular Docking Studies","authors":"GOPALASATHEESKUMAR K, Karthikeyen Lakshmanan, Anguraj Moulishankar, J. Suresh, D. K. Babu, V. Kalaichelvan","doi":"10.2139/ssrn.3625653","DOIUrl":null,"url":null,"abstract":"COVID-19 is the infectious pandemic disease caused by the novel\ncoronavirus. The COVID-19 is spread globally in a short span of\ntime. The Ministry of AYUSH, India which promotes Siddha and\nother Indian system of medicine recommends the use of formulation\nlike Nilavembu Kudineer and Kaba Sura Kudineer Chooranam\n(KSKC). The present work seeks to provide the evidence for the\naction of 74 different constituents of the KSKC formulation acting\non two critical targets. That is main protease and SARS-CoV-2 RNAdependent\nRNA polymerase target through molecular docking studies.\nThe molecular docking was done by using AutoDock Tools 1.5.6 of\nthe 74 compounds, about 50 compounds yielded docking results against\nCOVID-19 main protease while 42 compounds yielded against SARSCoV-\n2 RNA-dependent RNA polymerase. This research has concluded\nthat the KSKC has the lead molecules that inhibits COVID-19’s target\nof main protease of COVID-19 and SARS-CoV-2 RNA-dependent\nRNA polymerase.","PeriodicalId":8846,"journal":{"name":"Asian Journal of Organic & Medicinal Chemistry","volume":"20 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Organic & Medicinal Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2139/ssrn.3625653","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5
Abstract
COVID-19 is the infectious pandemic disease caused by the novel
coronavirus. The COVID-19 is spread globally in a short span of
time. The Ministry of AYUSH, India which promotes Siddha and
other Indian system of medicine recommends the use of formulation
like Nilavembu Kudineer and Kaba Sura Kudineer Chooranam
(KSKC). The present work seeks to provide the evidence for the
action of 74 different constituents of the KSKC formulation acting
on two critical targets. That is main protease and SARS-CoV-2 RNAdependent
RNA polymerase target through molecular docking studies.
The molecular docking was done by using AutoDock Tools 1.5.6 of
the 74 compounds, about 50 compounds yielded docking results against
COVID-19 main protease while 42 compounds yielded against SARSCoV-
2 RNA-dependent RNA polymerase. This research has concluded
that the KSKC has the lead molecules that inhibits COVID-19’s target
of main protease of COVID-19 and SARS-CoV-2 RNA-dependent
RNA polymerase.